Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

GlobalFoundries Inc. Ordinary SharesTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

GlobalFoundries Inc. Ordinary Shares vs Regeneron Pharmaceuticals Inc — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $48.08 (market cap $27.51B), while Regeneron Pharmaceuticals Inc trades at $746.63 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× GlobalFoundries Inc. Ordinary Shares's market cap, and GlobalFoundries Inc. Ordinary Shares pays the higher dividend (0.97%). Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

GFSREGN
Market Cap
$27.51B$76.14B
Volume
10,416,572500,239
Sector
TechnologyHealth
52-Week High
$89.96$852.03
52-Week Low
$32.24$557.73
Typical Hold Time
0 Days107 Days
Enterprise Value
$26.80B$70.85B
Dividend Yield
0.97%0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GlobalFoundries Inc. Ordinary Shares

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFS
51% Buy49% Sell
Avg holding period · 0 Days
REGN
98% Buy2% Sell
Avg holding period · 107 Days

Top news

Latest headlines on both assets

About GlobalFoundries Inc. Ordinary Shares

GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.

Read more on GFS →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →